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ABSTRACT
In contrast to numerous studies conducted to investigate the crucial role of fatty 
acid binding protein 5 (FABP5) in prostate cancer, investigations on the possible 
involvement of other FABPs are rare. Here we first measured the mRNA levels of 10 
FABPs in benign and malignant prostate cell lines and identified the differentially 
expressed FABP6 and FABP9 mRNAs whose levels in all malignant cell lines were 
higher than those in the benign cells. Thereafter we assessed the expression status 
of FABP6 and FABP9 in both prostate cell lines and in human tissues. FABP6 protein 
was overexpressed only in 1 of the 5 malignant cell lines and its immunostaining 
intensities were not significantly different between benign and malignant prostate 
tissues. In contrast, FABP9 protein was highly expressed in highly malignant cell 
lines PC-3 and PC3-M, but its level in the benign PNT-2 and other malignant cell 
lines was not detectable. When analysed in an archival set of human prostate 
tissues, immunohistochemical staining intensity for FABP9 was significantly higher 
in carcinomas than in benign cases and the increase in FABP9 was significantly 
correlated with reduced patient survival times. Moreover, the increased level of 
staining for FABP9 was significantly associated with the increased joint Gleason 
scores (GS) and androgen receptor index (AR). Suppression of FABP9 expression in 
highly malignant PC3-M cells inhibited their invasive potential. Our results suggest 
that FABP9 is a valuable prognostic marker to predict the outcomes of prostate cancer 
patients, perhaps by playing an important role in prostate cancer cell invasion.
INTRODUCTION
Prostate cancer is the most common male cancer in 
the developed countries and a worldwide male health threat 
[1, 2]. The incidence and mortality rate of prostate cancer 
increased throughout the entire 1980s and peaked in 1991 [3]. 
Since 1992, the serum prostate-specific-antigen (PSA) screen 
was used on a wide population use of this marker helped in 
early diagnosis of prostate cancer and thus contributed to 
improvements in subsequent 5-year survival rates [4–6]. 
Currently PSA is the most common marker used for both 
diagnosis and treatment management [7]. Although the 
widespread screening for PSA did lead to a degree of decline 
in mortality rates in some countries, many prostate cancer 
cases were not picked up by PSA screening in other countries. 
Several separate studies even suggested that PSA screening 
had only very limited or even no survival benefits [5, 8, 9], 
when a PSA cutoff level of 4 ng/ml was used to recommend a 
prostate biopsy (or not). Since PSA is produced and secreted 
by both benign and malignant prostate cells, the serum level 
of PSA can only reflect the size of the prostate gland, it cannot 
be used to distinguish the benign or malignant nature of the 
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cells. Thus PSA levels may also be increased in some benign 
prostatic diseases, such as prostatitis and benign prostate 
hyperplasia (BPH). Thus the real benefit of the widespread 
use of PSA screening is still debatable and the reliability of 
PSA as a prostate cancer marker is in serious question [5, 8, 
9]. Therefore, a reliable and accurate diagnostic or prognostic 
marker [6, 10, 11] that can be used to distinguish between 
benign and malignant prostatic disease is urgently needed for 
making speedy and correct treatment decisions [5, 12, 13].
To investigate the molecular mechanisms involved 
in the malignant progression of prostate cancer cells and 
to identify possible novel markers, we characterised the 
role of FABP5 and demonstrated its crucial function in 
promoting tumorigenicity and metastasis of prostate 
cancer [10, 14]. After FABP5 was proven to be a 
prognostic marker and potential treatment target [15–18], a 
frequently asked question was whether other FABP family 
proteins were also diagnostic or prognostic markers for 
prostate cancer. Twelve members of the FABP family with 
sizes between 14 to 15 kDa have been identified so far 
and 2 of them are restricted to fish. The other 10 FABPs 
are expressed in different human organs either singly or 
co-expressed with 1 or more other family members [19–
21]. FABPs are intracellular lipid-binding proteins that 
bind intracellular hydrophobic ligands such as long-chain 
fatty acids. FABPs have been suggested to be involved 
in secretion, uptake and intracellular transport of lipids 
to subcellular-organelles [19, 20]. FABPs have also been 
suggested to control cancer growth through co-ordination 
with other fatty acid transporters and carcinogens [22], 
steroids [23], hormones [24] and their derivatives [21].
In this study, we have investigated whether FABPs 
other than FABP5 can be used as diagnostic or prognostic 
markers; these may be involved in initial development 
and in malignant dissemination of prostate cancer cells. 
We first measured mRNA levels of 10 FABPs in benign 
and malignant human prostate epithelial cell lines with 
quantitative RT-PCR and found that FABP6 and FABP9 
mRNA levels in all malignant cell lines tested were 
higher than those in the benign cell lines. We then used 
Western blot and immunohistochemical staining to assess 
the expression status of FABP6 and FABP9 proteins in 
both prostate cell lines in culture and human prostatic 
tissues. The differences in expression profiles between 
benign and malignant cell lines and prostatic tissues were 
fully assessed and their possible value in diagnosis and 
prognosis have been systematically analysed.
RESULTS
Relative levels of mRNAs of different FABPs in 
prostate cells
Messenger RNAs of 10 different FABPs were 
isolated; their levels in the benign PNT-2 cells and 5 
malignant prostate cell lines were measured by quantitative 
RT-PCR and the results are shown in Figure 1. The high 
quality of mRNA from each cell line was confirmed by two 
clear bands representing both 18S and 28S sub rRNA units 
(Figure 1A). The high RNA integrity number (RIN) of the 
samples (between 9.0 and 9.6) showed that the total RNAs 
were intact (Figure 1B). The relative levels of mRNAs 
of 10 different FABPs in 6 different cell lines are shown 
in Figure 1C. Assessing transcription profiles between 
the benign and malignant cell lines showed that FABP4, 
FABP5, FABP6, FABP9 and FABP12 exhibited clearly 
higher levels in all malignant cell lines. For FABP1, FABP3, 
FABP2 FABP7 and FABP8, no clear and unified differences 
in their mRNA levels were identified when malignant were 
compared with benign cell lines.
Expression of FABP6 and FABP9 in prostate 
cells at the protein level
Differential expression of FABPs in levels of protein 
is shown in Figure 2. When analysed by Western blot 
(Figure 2A), a single 14 kDa FABP6 band was detected in 
all prostate cell lines as well as a positive control MCF7 
breast cancer cells (Figure 2A: a). Quantitative analysis 
showed that the level of FABP6 in highly malignant 
Du145 cells was more than 2 times of that in the benign 
PNT-2 cells (Student’s t-test, p = 0.01). The levels of 
FABP6 in low malignant LNCaP cells, moderately 
malignant 22RV-1 cells, highly malignant PC-3 and 
PC3-M cells were lower than that in PNT-2 cells (Figure 
2A: b), but the differences were not significant (Student’s 
t-test, p>0.05). FABP9 protein running as a single band at 
14 kDa was highly expressed in 2 of the 5 malignant PC-3 
and PC3-M cells, but its expression in other prostate cells 
including benign PNT-2 cells was not detectable (Figure 
2A: c). Further quantitative analysis showed (Figure 2A: 
d) that the level of FABP9 in the highly malignant cells 
PC3-M was a significant 20% higher than that in PC-3 
(Student’s t-test, p= 0.006).
Detection of FABP6 and FABP9 in prostate 
tissues
The expression of FABP6 and FABP9 in the 
control, BPH and carcinoma tissues was detected by 
immunohistochemical (IHC) staining and representative 
staining patterns are shown in Figure 2B and quantified 
in Table 1. IHC showed nuclear staining only on BPH 
and carcinoma cells with antibodies to FABP6 (identified 
by the arrow), no cytoplasmic staining was observed 
(Figure 2B). Results of anti-FABP6 staining were shown 
in Table 1A. Nuclear staining was observed in all 33 BPH 
tissues (100%): 3 (9%) stained weakly, 25 (76%) stained 
moderately, and 5 (15%) stained strongly. Among the 92 
adenocarcinomas, 28 (30%) were unstained, 11 (12%) 
stained weakly, 23 (25%) stained moderately and 30 
(33%) stained strongly. Although FABP6 was detected in 
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Figure 1: Quantitative PCR analysis of levels of FABP mRNAs in benign and malignant prostate epithelial cells. Benign 
cell line PNT-2, weakly malignant cell line LNCaP, moderately malignant cell line 22RV-1 and highly malignant cell lines Du145, PC-3 
and PC3-M were cultured to 80% confluence and harvested for mRNA extraction. The quality of the mRNA was assessed by a 2100 Bio-
analyser. A. the electrophernograms of the gel-like images of mRNAs from 6 cell lines and from the RNA ladder (marker). B. the double 
peaks representing 18S and 28S sub-units and the RNA integrity numbers (RIN) of the samples from different cell lines. C. relative levels 
of FABP mRNAs detected in benign and malignant prostate cell lines.
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Figure 2: Expression of FABP6 and FABP9 in prostate cell lines and tissues. A. Measurement of FABPs in benign and 
malignant prostate cells. a. Western blot analysis of FABP6 in benign and malignant prostate cells. b. relative levels of FABP6 in different 
cell lines. The level of FABP6 in the benign PNT-2 cells was set at 1.0; levels in other cell lines were obtained by relating to that in PNT-
2 cells. The positive control (MCF-7) was suggested by the manufacturer of the antibody. The results were obtained from 3 separate 
experiments (mean ± SD). c. Western blot analysis of FABP9 in benign and malignant prostate cells. d. relative levels of FABP9 in different 
cell lines. Since the expression in PNT-2, LNCaP, 22RV-1 and Du145 is not detectable, their levels were expressed as “0”. The level in PC-3 
cells was set at 1.0, the level in PC3-M cells was obtained by relating to that in PC-3. The results were obtained from 3 separate experiments 
(mean ± SD). B. Immunohistochemical detection of FABP6 and FABP9 in benign and malignant prostate tissues. Positive controls for 
FABP6 and FABP9 were breast cancer tissue and normal kidney tissue respectively (x100). For anti-FABP6, only nuclear staining was 
observed (identified in the insert by the arrow). For anti-FABP9, only cytoplasmic staining was observed (identified in the insert by the 
arrow). Carcinomas were divided into three categories according to their combined GS: weakly malignant (or GS ≤5), moderately (or GS 
6-7) and high malignant (or GS 8-10) tissues.
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the nucleus of the cells, the staining intensities between 
BPH and carcinoma tissues were not significantly different 
(χ2 test, p>0.08).
The staining of FABP9 in carcinoma tissues was 
cytoplasmic only (identified by the arrow) (Figure 2B) and the 
results are shown in Table 1B. Among 36 BPH cases 25 (70%) 
were unstained and 11 (30%) stained weakly. Among 86 
adenocarcinomas, staining was weak in 31 (36%), moderate 
in 39 (46%) and strong in 15 (18%) cases (Table 1B). No 
nuclear staining was observed in any BPH and carcinoma 
samples. Comparing the FABP9 expression between BPH 
and carcinomas, the staining intensity in carcinoma tissues 
was significantly stronger (χ2 test, p<0.0001).
Correlation of FABP9 expression to GS
According to their GS, carcinomas were divided 
into 3 groups: low (GS ≤5), moderate (GS 6-7) and high 
malignant (GS 8-10), as shown in Table 1B. Of the 28 
weakly malignant carcinoma tissues, 22 (78%) stained 
weakly, 6 (22%) stained moderately, none of them stained 
strongly. Among the 25 moderately malignant cases 
with GS 6-7, 7 (27%) stained weakly, 13 (53%) stained 
moderately and 5 (19%) stained strongly. Of the 33 highly 
malignant cases with GS 8-10, 2 (6%) stained weakly, 20 
(63%) stained moderately and 11 (31%) stained strongly. 
The intensity of FABP9 staining in moderately malignant 
cases was significantly higher than that in low malignant 
cases (χ2 test, p<0.00001). Highly significant difference 
was also observed in staining intensities between low 
malignant cases and highly malignant cases (χ2 test, 
P<0.00001). When the staining intensities between the 
moderately malignant and the highly malignant cases were 
compared, the difference was not statistically significant 
(χ2 test, p =0.09).
Relationship between patient survival and levels 
of FABP9, GS, AR index and PSA
The cumulative survival of patients was plotted 
against the time in months using Kaplan-Meier survival 
graphs for different levels of the 4 parameters and the 
significance for each parameter was assessed by log-rank 
tests as shown in Figure 3. When the correlation between 
patient survival time and the FABP9 staining intensity 
was assessed (Figure 3A), the median survival time for 
patients with weak staining for FABP9 was 60 months 
which was significantly longer than those patients with 
moderate (24 months) and strong (18 months) staining 
for FABP9, respectively. Overall, the increased FABP9 
staining intensity was significantly correlated with 
reduced patient survival time (log-rank test, p = 0.02).
Table 1: Expression status of FABP6 and FABP9 in benign and malignant prostate tissues
Table 1A: Immunohistochemical stains of tissues with antibody against FABP6
FABP6 Nuclear stain intensities a No. of cases
Tissues 0 + ++ +++
BPH 0 3 25 5 33b
Carcinomas (Total) 28 11 23 30 92b
GSc ≤5 14 0 6 3 23
GSc 6-7 10 4 11 10 35
GSc 8-10 4 5 8 17 34
a Staining was observed only in the nucleus of the cells. bTotal BPH were 36 and total carcinomas were 97, but some cases 
were excluded because of technical reasons. c Combined GS.
Table 1B: Immunohistochemical stains of tissues with antibody against FABP9
FABP9 Cytoplasmic stain intensities a No. of cases
Tissues 0 + ++ +++
BPH 25 11 0 0 36
Carcinomas (Total) 0 31 39 16 86b
GSc ≤5 0 22 6 0 28
GSc 6-7 0 7 13 5 25
GSc 8-10 0 2 20 11 33
a Staining was observed only in the cytoplasm of the cells. b Total carcinomas were 97, but some cases were excluded 
because of technical reasons. c Combined GS.
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When the correlation between the patient survival 
time and AR index level was assessed (Figure 3B), 
the median survival time for patients with weak, 
moderate and strong staining for FABP9 was 60, 24 
and 24 months, respectively. The overall increase in 
intensity of AR staining was of borderline significance 
in correlation with reduced patient survival time (log-
rank test, p = 0.052).
When the correlation between patient survival time 
and the blood level of PSA was assessed (Figure 3C), the 
median survival time for patients with low (<10ng/ml) 
and high (≥10ng/ml) PSA levels were 48 and 18 months, 
Figure 3: Kaplan-Meier survival curves of patients with prostate cancer. The cumulative survival of patients was 
plotted against the time in months for different levels of 4 parameters. A. different GS: group 1, GS ≤5 (n=17); group 2, 
GS 6 to 7 (n=38); group 3, GS 8 to 10 (n=45). B. different AR indices: low group, <4 (n=41); moderate group, 4-6 (n=50); 
high group, 6-9 (n=11). C. different levels of PSA: group 1, PSA <10 ng/ml (n=38) and group 2, PSA ≥10 ng/ml (n=64). 
D. different levels of staining for FABP9: group 1, weakly positive (n=28); group 2, moderately positive (n=38); group 3, 
strongly positive (n=21).
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respectively. The difference was not statistically significant 
(log-rank test, p = 0.246).
When the relationship between patient survival 
time and GS was assessed (Figure 3D), the median 
survival times for patients with low GS (80 months) was 
significantly longer than for those patients with moderate 
(60 months) and high GS (12 months), respectively. The 
increased GS was significantly correlated with reduced 
patients’ survival time (log-rank test, p < 0.0001).
Correlation of FABP9 expression with levels of 
GS, AR index and PSA
Assessment of correlation between the intensity 
of staining for FABP9 and GS, AR index and PSA level 
is shown in Figure 4. Correlation between the staining 
intensity of FABP9 and GS is illustrated by box plot 
(Figure 4A) and the result assessment showed that 
expression of FABP9 was significantly higher in cases with 
Figure 4: Box plot of correlations amongst 3 different variables. A. Correlation between the stain intensity for FABP9 and the 
Gleason score (GS) in 3 groups of patients with prostate cancer: GS < 6 (low), GS 6 to 7 (moderate) and GS 8 to 10 (high). B. Correlation 
between stain intensity for FABP9 and androgen receptor (AR) index in 3 groups of patients with prostate cancer: weak (W), moderate (M) 
and high (S) levels of FABP9. C. Correlation between stain intensity for FABP9 and prostatic specific antigen (PSA) level in 3 groups of 
patients with prostate cancer: weak (W), moderate (M) and high (S) levels of FABP9.
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high GS than in those cases with low GS (Mann-Whitney 
U test, p < 0.001). The staining intensity for FABP9 in 
cases with moderate GS (6 to 7) was significantly higher 
than that in cases with low GS (Mann-Whitney U test, p 
= 0.007). However, the difference in staining for FABP9 
between cases with high GS and those with moderate GS 
was not significantly different (Mann-Whitney U test, p 
= 0.091).
Box plot of the correlation between staining 
intensity for FABP9 and AR index showed that the AR 
index level was significantly higher in cases with strong 
staining for FABP9 than in those cases with weak staining 
for FABP9 (Figure 4B) (Mann-Whitney U test, p = 
0.03). However, the differences in AR index levels either 
between cases with moderate and weak FABP9 staining 
(Mann-Whitney U test, p = 0.11) or between cases with 
strong and weak staining for FABP9 (Mann-Whitney U 
test, p = 0.084) were not statistically significant.
For the correlation between the staining intensity 
of FABP9 and PSA level (Figure 4C), box plots showed 
that the differences in PSA levels between cases with 
strong and weak stains for FABP9 (Mann-Whitney U test, 
p = 0.142), between strong and moderate stains (Mann-
Whitney U test, p = 0.098) and between moderate and 
weak stains for FABP9 (Mann-Whitney U test, p = 0.812) 
were not significantly different.
FABP9 knockdown and its effect on invasiveness
Knockdown of FABP9 mRNA in highly malignant 
prostate cancer cells and testing the invasiveness of the 
transfectants expressing reduced levels of FABP9 (not 
via FABP5 suppression) are shown in Figure 5. Western 
blot analysis was used to assess the effect of mRNA 
knockdown on FABP9 expression in PC3-M cells 
(Figure 5A). When the PC3-M cell line was transiently 
transfected for 48 hours with 3 different siRNAs, Western 
blots showed that the levels of FABP9 expression after 
transfection were reduced (Figure 5A. a). Quantitative 
analysis showed that the levels of FABP9 in scramble 
control and PC3-M treated with transfection reagent 
alone were similar to that in the parental PC3-M cells. 
The relative levels in the other three PC3-M transfectants 
with siRNA 1, 2 and 3 were (means±SD) 0.86±0.14, 
0.75±0.35 and 0.45±0.30, respectively. The most efficient 
suppression was achieved by siRNA-3 (up to 60%) 
(Student’s t-test, p< 0.0001) (Figure 5A. b). Therefore, 
siRNA-3 was identified as the most effective suppresser 
and its sequence was used to design double-stranded 
shRNA for stable transfection.
For stable transfection, shRNAs were cloned into 
the psiRNA-h7SKGFPzeo plasmid and then transfected 
into the PC3-M cell line to knockdown stably FABP9 
mRNA. When Western blots were used to measure the 
level of FABP9 from different individual colonies of 
transfectants, a single 14 kDa FABP9 band was detected 
and levels of FABP9 in scramble control PC3-M, parental 
PC3-M and 5 single transfectant clones are shown in 
Figure 5A-c. Further quantitative analysis showed that 
the level of FABP9 in the scramble control was similar 
to that in the parental PC3-M cells. The relative levels of 
FABP9 in 1-5 single colonies were reduced by 25%, 15%, 
43%, 50% and 91%, respectively (Figure 5A. d). Thus cell 
lines established from clone 4 and clone 5 were selected 
as moderately (PC3M-FABP9-siM) and highly (PC3M-
FABP9-siH) suppressed transfectant lines. To confirm 
that the suppression was not via FABP5, Western blot 
analysis was used to assess the effect of FABP9 mRNA 
knockdown on FABP5 expression in PC3-M cells (Figure 
5A. e). Quantitative analysis showed that the levels of 
FABP5 in PC3M-FABP9-siM and PC3M-FABP9-siH 
were similar to that in the parental PC3-M cells (Figure 
5A. f). The effect of FABP9-supression on invasiveness of 
prostate cancer cells was evaluated by an invasion assay, 
as shown in Figure 5B (inserted pictures). The mean 
number of invaded cells from scramble control, PC3M-
FABP9-siM and PC3M-FABP9-siH were 43±7, 26±4 and 
15±5 respectively, representing significant reductions by 
39.5% (χ2 test, p = 0.008) and 65.1% (χ2 test, p = 0.001), 
respectively.
DISCUSSION
FABPs are intracellular lipid-binding proteins that 
bind intracellular hydrophobic ligands such as saturated 
or unsaturated medium- or long-chain fatty acids and 
consist of at least 12 members. Previous studies showed 
that some FABPs were implicated in progression of 
several cancer types and could be used as tumour 
biomarkers [25–27]. FABP5 played a crucial promoting 
role in tumorigenicity and metastasis of prostate cancer 
[10, 14]. It was also involved in malignant progression 
of pancreatic cancer [28]. It was reported that the FABP5 
and FABP6 were overexpressed and might play promoting 
roles in colorectal cancer [27, 29]. FABP1 was shown to 
play a key role in breast cancer cells and has the potential 
to serve as a diagnostic marker [30]. FABP7 was shown to 
be a specific biomarker for renal cell carcinomas [31]. In 
addition, increased expression of FABP7 was associated 
with proliferation and invasion of melanoma cells [32]. 
Although functional characterisation work and other 
studies demonstrated that FABP5 and other FABPs may 
be prognostic markers and treatment targets for different 
cancer types, the potential involvement of other FABPs 
in malignant progression of prostate cancer had not been 
fully investigated. Amongst the 12 members of FABP 
family proteins, FABP10 and FABP11 are restricted to 
fish only and not expressed in Homo sapiens [33–35]. 
Thus in this study, we measured mRNA levels of the 
other 10 different FABPs in prostate epithelial cells to 
assess whether any of them were differentially expressed 
between benign and malignant phenotypes. The results 
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Figure 5: Knockdown of FABP9 mRNA in highly malignant prostate cancer cells and testing the invasiveness of the 
transfectants expressing reduced levels of FABP9. A. Effect of mRNA knockdown on FABP9 expression in PC3-M cells. a. Western 
blot analysis of FABP9 expressed in PC3-M cells and cells transiently transfected with 3 different siRNAs. To standardize the immune 
reactions, β-actin antibody was incubated with the same blot. b. relative levels of FABP9 in PC3-M cells after transient transfection. The 
level of FABP9 in parental PC3-M was set at 1.0 and levels expressed in other transiently-transfected cells with the controls and different 
siRNAs were obtained by relating to that in parental cells. c. Western blot analysis of FABP9 in control PC3-M cells and 5 different clones 
generated by transfection with the shRNA based on siRNA-3. To standardize the immune reactions, β-actin antibody was incubated with the 
same blot. d. The relative levels of FABP9 in PC3-M transfected with scramble shRNA control was set at 1.0 and levels expressed in other 
transfected cell lines were obtained by comparing with the control. e. Western blot analysis of FABP5 in transfectants expressing reduced 
levels of FABP9. f. The relative levels of FABP5 in PC3-M cells and transfectants expressing reduced levels of FABP9. (Continued )
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showed that FABP4, FABP5, FABP6, FABP9 and FABP12 
exhibited clearly higher levels in all tested malignant 
cell lines compared to their levels in the benign PNT-2 
cells (Figure 1). For the remained of the FABPs, no clear 
differences were observed and therefore they are unlikely 
to be involved in carcinogenesis of prostate cancer.
Amongst the other differentially expressed FABPs, 
FABP4 was released from adipocytes, implicated in 
obesity [36] and its possible involvement in the malignant 
progression of prostate cancer has been investigated 
previously [37]. Although FABP6 was differentially 
expressed at the level of its mRNA, its expression at 
the protein level was not significantly different between 
the BPH and the carcinoma tissues (Table 1A) and it 
was expressed in nucleus. Most FABPs are fatty acid 
transporters and are localised mainly in cytoplasm 
(not fixed in a specific site) and move in and out of 
cell membrane to transport fatty acids. Why FABP6 
is localised in nucleus is not known, since it is not 
differentially expressed between benign and malignant 
tissues, it is unlikely to be related to prostate cancer. 
FABP12 is the most recently discovered member of the 
FABP family, its mRNA level in malignant cells was 3-105 
fold higher than that in benign PNT-2 cells (Figure 1). This 
result indicated that FABP12 may play an important role 
in prostate cancer and thus a separate investigation has 
been conducted to study FABP12. The result on FABP12 
study will be published separately from this work.
In this study, the main work was focused on 
FABP9. At the mRNA level (with a size of 365 KB) [38], 
its expression in malignant cells was 5-47 fold higher 
than that in benign cells. When Western blot was used 
to measure FABP9 protein, its expression was high in 
highly malignant cell lines PC-3 and PC3-M, whereas 
its expression in the benign and low-malignant cells was 
not detectable (Figure 2A). This result demonstrated that 
elevated levels of FABP9 is correlated with increased 
malignant characteristics, indicating that FABP9 may 
play an important role in progression and development of 
prostate cancer.
The immunohistochemical analysis showed 
the staining intensity of FABP9 was significantly 
higher in carcinomas than in BPH (Table 1B) and the 
increased FABP9 stain was significantly correlated 
with the increased degree of malignancy, as reflected 
by the increased GS. Since the combined GS is the 
most commonly used parameter to stratify the stage of 
prostate cancer, the fact that the increased FABP9 level 
is significantly associated with the increased GS suggests 
that FABP9 expression may be a useful prognostic factor. 
To confirm this, further assessment was made on the 
relationship between FABP9 expression and the duration 
of patient survival time. The result showed that the overall 
increase in FABP9 was significantly correlated with 
reduced patient’s survival time (log-rank test, p < 0.02; 
Figure 3A). The median survival for patients with weak 
staining for FABP9 was 60 months which was significantly 
2.5- and 3.3- times longer than those of the patients with 
moderate (24 months) and strong (18 months) stains for 
FABP9, respectively. The result also showed that patient 
survival time was significantly associated (log-rank test, p 
< 0.0001; Figure 3D) with increased GS. These findings 
suggest that increased level of FABP9 expression is 
significantly correlated with the poor prognosis in terms 
of patient’s survival time, similar to the prognosis made 
according to GS.
Both PSA and AR index (a parameter used to 
measure the staining intensity of AR [39]) are used as 
Figure 5: (Continued ) Knockdown of FABP9 mRNA in highly malignant prostate cancer cells and testing the 
invasiveness of the transfectants expressing reduced levels of FABP9. B. The effect of FABP9 suppression on invasiveness of 
transfectant cells. The results (mean ± SD) were obtained from 3 separate experiments. Insert picture: 3 panels represent the invasiveness 
of the control, moderately suppressed (M) and highly suppressed (H) cells respectively.
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biomarkers for prostate cancer. Although AR plays a key 
role in carcinogenesis of prostate cancer, the results in 
this study showed that the AR index is only of borderline 
significance in its association with reduced patient survival 
time (log-rank test, p = 0.052; Figure 3B). PSA is the most 
commonly used biological marker for prostate cancer, but 
the result in this study showed that correlation between 
PSA level and patients’ survival time was not significantly 
correlated (log-rank test, p = 0.246; Figure 3C). Therefore, 
neither PSA nor AR index level were reliable prognostic 
markers for prostate cancer.
When the correlation between FABP9 expression 
and AR index was assessed, the level of the AR index 
was significantly higher in cases with strong FABP9 
expression than in cases with weak expression of 
FABP9 (Mann-Whitney U test, p = 0.03; Figure 4B). 
In contrast, when FABP9 expression and PSA level 
was assessed, the differences in patient PSA level were 
neither significant between strong and weak FABP9 
staining (Mann-Whitney U test, p = 0.142) nor between 
strong and moderate FABP9 staining (Mann-Whitney 
U test, p = 0.098) (Figure 4C). This result showed that 
there was no correlation between FABP9 levels and PSA 
levels in blood, and suggested that PSA did not reflect the 
degree of malignancy of the carcinomas. Like some other 
previous studies, this work raised questions as to the real 
value of using PSA as a biomarker for prostate cancer. 
The real benefit of the widespread use of screening for 
PSA is still a matter of debate [5, 8, 9]. It is confirmed 
that only 30% of patients with an abnormal PSA value 
(above 4 ng/ml) were finally diagnosed with prostate 
cancer, leading to both an over-biopsy for diagnosis and 
an over-treatment of low-risk patients[8]. Identification 
of novel biomarkers that can distinguish between the 
benign and the malignant nature of each case and can 
predict the severity of malignancy may provide a new 
way of disease stratification for prostate cancer and hence 
reduce unnecessary biopsies (a very invasive procedure) 
and nonessential treatments. The results in this study 
suggest that the nature of the patient case and the degree 
of malignancy are reflected by the level of FABP9 in the 
primary tumors. The results also suggest that FABP9 is 
a valuable prognostic marker to predict the outcomes of 
prostate cancer patients. FABP9 is expressed in the testis 
and has several important physiological roles in sperm 
development; including attachment of the acrosome to the 
sperm nucleus during fertilization and spermatogenesis 
[20, 40, 41]. Further studies are needed to investigate 
whether the level of immunoreactive FABP9 can be used 
to replace (or partially replace) GS so that, at least in some 
cases, the biopsy procedure can be avoided.
To study the biological significance of increased 
FABP9 in highly malignant prostate cancer cells, 
knockdown of FABP9 mRNA was performed via RNAi 
in highly-expressing PC3-M cells to establish highly- 
and moderately-suppressed transfectant cell lines, named 
PC3M-FABP9-siH and PC3M-FABP9-siM, respectively. 
When tested in an invasion assay, the number of invaded 
cells from PC3M-FABP9-siH cells, whose level of 
FABP9 was reduced by 91%, was reduced by 2.8- fold. 
In contrast that from PC3M-FABP9-siM, whose level of 
FABP9 was reduced by only 50%, was reduced by 1.6-
fold (Figure 5A. d). Thus the reduced level of expression 
of FABP9 is closely related to the reduced invasive ability 
of the highly-malignant prostate cancer cells (Figure 5B). 
This reduction is not achieved by changing the level of 
FABP5 (Figure 5A. f). This result suggests that FABP9 
may play an important role in malignant progression of 
prostate cancer cells by promoting cellular invasion. More 
investigations are needed to study the role of FABP9 in 
carcinogenesis and the possibility of using it as a treatment 
target. In conclusion, FABP9 is overexpressed in highly 
malignant prostate cells and tissues. The increased level 
of FABP9 is significantly correlated with the increased 
malignancy of the carcinomas, as reflected by the 
increased GS. FABP9 is also significantly correlated to 
reduced patient survival time. FABP9 is a more reliable 
prognostic marker than PSA to predict the outcome of 
prostate cancer patients and it may play an important role 
in the invasion of prostate cancer cells.
MATERIALS AND METHODS
Cell lines and culture conditions
The following seven cell lines were used: MCF7 
breast cancer cell line (the positive control for FABP6), 
benign prostate epithelial cell line PNT-2 [42, 43], weakly 
malignant cell line LNCaP derived from moderately-
differentiated lymph node metastasis [44], moderately 
malignant cell line derived from a xenograft 22RV-1 and 
highly malignant cell lines Du145 derived from brain 
metastasis [45], PC-3 and PC3-M cell lines derived from 
poorly-differentiated bone metastasis [46]. All cell lines 
were grown and maintained as monolayer cultures in 
RPMI1640 nutrient medium (Invitrogen, Paisly, UK), 
supplemented with 10% (vol/vol) foetal calf serum, 
penicillin (100 U/ml) (Biosera, East Sussex, UK), 
streptomycin (100 µg/ml) and L-glutamine (Invitrogen). 
For LNCaP cells, sodium pyruvate (100 µg/ml) (Sigma, 
Grillingham, UK) was also added into the culture medium.
Quantitative RT-PCR
DNA sequence spanning exon junctions of all FABP 
genes were used to design the real-time PCR primers. The 
total RNAs were extracted and purified from 6 different cell 
lines using RNAeasy Mini Kit. The quality and integrity of 
the mRNA was assessed using RNA 6000 Nano LabChip 
on Agilent 2100 Bio-analyser. The RNA templates were 
converted into a complementary DNA (cDNA) using 
reverse transcriptase. The real-time PCR mixtures for all 
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FABPs and β actin were prepared with 2x brilliant SYBR 
Green qPCR master mix, 5µM forward primer, 5µM reverse 
primer, cDNAs and nuclease water. The reactions were 
centrifuged and placed in a real-time PCR thermocycler. 
The relative fold differences of FABPs mRNAs between 
benign and malignant cells were calculated.
Western blotting
FABP6 and FABP9 expression in prostate cell 
lines was detected by Western blots using ECL system 
(Amersham Pharmacia Biotech, Buck, UK) [11]. The 
polyvinylidene difluoride (PVDF) membrane was first 
blocked with 5% (v/v) of blocking solution and then 
incubated with primary antibody, which was either 
anti-FABP9 antibody (1:500 sheep polyclonal FABP9 
antibody, R&D Company) or anti-FABP6 antibody (1:500 
Rabbit polyclonal FABP6 antibody, Abcam, UK) for 1 
hour at 4°C. The membrane was incubated with secondary 
antibody conjugated with horseradish peroxidase. The 
secondary antibody was either rabbit anti-mouse antibody 
(1:10000) for FABP6 or mouse anti-sheep antibody 
(1:10000) for FABP9 (Dako, Cambridge, UK). Antibody-
bound proteins were visualized by exposure to Kodak 
XAR-5 film at room temperature. The intensity of the peak 
areas of the bands was measured using an Alpha Imager 
2000 densitometer (Alpha Innotech, Cannock, UK). To 
correct for possible loading discrepancies, the membrane 
was incubated with an antibody to β-actin.
Tissue samples and patient data
Human prostate cancer tissues used in this work 
were obtained from an archival set of prostate cancer cases 
that were held in the archives of the original Pathology 
Department and our Molecular Pathology Laboratory, as 
described previously [11, 47]. Those patients who were 
originally diagnosed with prostate cancer but died from 
other causes were excluded from this study. All samples 
were taken from patients with an age range of 67 to 73 
years who had undergone trans-urethral resection of 
the prostate (TURP) in the Royal Liverpool University 
Hospital between 1995 and 2001. This study, approved 
by the National Science Ethics Committee, was carried 
out in accordance with the Medical Research Council 
guidelines (project reference number: Ke; 02/019). All 
35 BPH samples and 97 adenocarcinomas had been 
preserved in 10% (v/v) formalin and embedded in paraffin 
wax [48]. Cases were re-examined independently by two 
qualified pathologists and the carcinomas were classified 
into weakly, moderately and highly malignant tissues 
according to their combined GS.
Immunohistochemistry staining
Histological sections were cut from formalin-
fixed, paraffin-embedded tissues (4-µm), de-waxed 
and dehydrated in xylene and ethanol, respectively 
[47]. Tissues were incubated in methanol and hydrogen 
peroxide (3%) for 12 min. Sections were incubated with 
primary anti-FABP9 antibody (1:500 sheep polyclonal 
FABP9 antibody, R&D Company) or with anti-FAB6 
antibody (1:50 rabbit polyclonal FABP6 antibody, Sigma-
Aldrich, UK) at room temperature for 1 hour and then 
incubated with a rabbit anti-sheep IgG linker or mouse 
anti-rabbit IgG linker (Vector Laboratories, Burlingame, 
CA, USA) for 30 min. Sections were incubated with 
Envision™ FLEX DAB+ chromogen mixed with 
Envision™ FLEX substrate (ldop/ml) (Dakocytomation, 
Ely, UK) for 15min. All sections were counterstained 
with hematoxylin, mounted on glass slides with cover slip 
using DPX mountant, and observed by light microscope 
for scoring.
Scoring immunoreactivity
A standard light microscope (x400) was used 
to evaluate cytoplasmic and nuclear expression of 
FABP6 and FABP9. Immunoreactivity was examined 
independently by two qualified observers. The intensity 
of cytoplasmic staining was classified into 4 categories: 
unstained, weakly, moderately and strongly stained 
which were expressed as 0 (-), 1 (+), 2 (++) and 3 (+++), 
respectively. Nuclear staining was assessed by the 
intensity of staining which was expressed as 0 (-), 1 (+), 
2 (++) and 3 (+++). The differences in scoring categories 
between 2 observers were <5%.
Statistical analysis
The analysis was performed using the Statistical 
Package for Social Sciences (SPSS). Correlation 
between FABP6 and FABP9 expression and the benign 
and malignant prostate tissues were assessed by χ2 test. 
Kaplan Meier plots were used to separate survival times 
of patients with differentially stained samples for FABP6 
or FABP9. The graphs were labelled the significance 
association with Log Rank test (p value). Correlation 
between FABP9 and GS, AR or PSA level was assessed 
via box plot and Mann Whitney U 2x3 tests. Statistical 
significance was defined as P < 0.05.
RNA interference
Bioinformatics & Research computing Software 
(Whitehead siRNA selection program) was used to select 
three different candidate sequences for FABP9 siRNA. 
Specificity of these sequences to FABP9 was confirmed 
by Blast search. Oligonucleotides made from these 3 
sequences were commercially purchased (Ambion Life 
technologies, USA):
Sequence 1, sense strand 5’: GTACCTCGGTTAGT
GAAACCGACAGTTCAAGAG; antisense strand 5’: AG
CTTTTCCAAAAAGGTTAGTGAAACCGACAGTCTC
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TTGAACTGTCGGTTTCACTAACCGAG. Sequence 2, 
sense strand 5’: GTACCTCCTCAATGATTCACGTCCA
ATCAAGAGTTGGACGTGAATCATTGAGTTTTTGG
AAA; antisense strand 5’: AGCTTTTCCAAAAACTCA
ATGATTCACGTCCAACTCTTGATTGGACGTGAATC
ATG. Scramble negative control, sense 5’: GTACCTCGC
AGACCTTCCCATATAATTCAAGAGATTATATGGGA
AGGTCTGCTTTTTGGAAA; antisense 5’: AGCTTTTC
CAAAAAGCAGACCTTCCCATATAATCTCTTGAATT
ATATGGGAAGGTCTGCGAG.
PC3-M cell line was transfected transiently with 
the X-tremeGENE siRNA Transfection Reagent (Roche) 
and the level of FABP9 was measured by Western blot 
analysis after the transient transfection of each of the 
3 candidate sequences. The most efficient suppressor 
sequence was identified from the blot and was used 
to design short hairpin RNA (shRNA) using siRNA 
Wizard™ Software(InvivoGen, USA). Two shRNA inserts 
containing RNAi sequences against FABP9 were cloned 
into the psiRNA-h7SKGFPzeo plasmid (InvivoGen, USA) 
separately. PC3-M was stably transfected with vectors 
containing different FABP9 shRNAs using X-tremeGENE 
HP DNA Transfection Reagent (Roche, Germany). In a 
separate transfection, a vector containing scrambled RNA 
was used as a control. Transfected cells were cultured in 
a selective medium containing Zeocin (100μg/ml) (Life 
Technologies) for 3-4 weeks until the colonies were 
visualized. Ring cloning technique was used to isolate 
five single colonies to establish FABP9-supressed PC3-M 
transfectants and the level of FABP9 in these transfectants 
was measured by Western blot analysis.
Invasion assay
The invasiveness of the transfectants was assessed 
in a BD BioCoat™ Matrigel™ Invasion Chamber (BD 
Biosciences, USA). After 24-hour starvation, PC3-M 
and transfected cells at a density of 2.5x104 cells/ml 
were loaded into every upper compartment of chambers. 
Routine medium was loaded in the lower compartment and 
serum-free medium was used as negative control for each 
cell line. The chambers were maintained in a humidified 
tissue culture incubator at 37°C, 5% CO2 (v/v). After 24-
hour cells in the upper compartment were removed and 
washed with PBS. Then, the cells, which invaded the 
lower part, were fixed and stained with 2% (v/v) crystal 
violet for 10 minutes. The number of invaded cells was 
counted using a light microscope.
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